Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yujia Dai

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Nature Chemical Biology|January 24, 2017
The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrityKenneth D Bromberg, Taylor R H Mitchell, Anup K Upadhyay, et al.
Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Nature Chemical Biology|January 24, 2017
The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrityKenneth D Bromberg, Taylor R H Mitchell, Anup K Upadhyay, et al.
Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.
Pageof 4